Carbergoline for Antipsychotic Induced Hyperprolactinemia.

Summary

The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia. The main question it aims to answer : Is the severity of positive and negative symptoms affected by the use of cabergoline? Researchers will compare cabergolin to placebo to see if positive and negative symptoms are equel in both groups. Participants will, in a blinded manor, take either placebo tablets or cabergoline for 12 weeks. The severity of positive and negative symptoms will be evaluated before and after the intervention in both groups.

Timeline

Start

2026-05-01

Primary completion

2028-05-01

Completion

2029-05-01

Publications

• Background Kuroki T, Watanabe Y, Yamai S, Obara Y, Takizawa K. [Detection of Neisseria gonorrhoeae antigens by an enzyme immunoassay (Gonozyme)]. Kansenshogaku Zasshi. 1985 Dec;59(12):1236-40. doi: 10.11150/kansenshogakuzasshi1970.59.1236. No abstract available. Japanese.
• Background Gonzalez-Rodriguez A, Labad J, Seeman MV. Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109941. doi: 10.1016/j.pnpbp.2020.109941. Epub 2020 Mar 31.
• Background Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Dirani R, Menzin J. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010 Dec;61(12):1239-47. doi: 10.1176/ps.2010.61.12.1239.

Drugs

Indications